Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon.

Deville C, Both S, Bui V, Hwang WT, Tan KS, Schaer M, Tochner Z, Vapiwala N.

Radiat Oncol. 2012 May 23;7:76. doi: 10.1186/1748-717X-7-76.

2.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18.

PMID:
20171807
3.

Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.

Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1389-96. doi: 10.1016/j.ijrobp.2011.04.041. Epub 2011 Jun 12.

PMID:
21664069
4.

Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.

Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14.

PMID:
21163587
5.

Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.

Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024. Epub 2011 Apr 7.

PMID:
21477939
6.

Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, van Herk M, Heemsbergen WD.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):737-44. doi: 10.1016/j.ijrobp.2014.12.017.

PMID:
25752386
7.

Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204-12. doi: 10.1016/j.ijrobp.2010.10.009. Epub 2010 Dec 16.

PMID:
21167653
8.

High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.

Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA, van Vulpen M.

Radiat Oncol. 2008 May 21;3:15. doi: 10.1186/1748-717X-3-15.

9.

Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.

Cheng JC, Schultheiss TE, Nguyen KH, Wong JY.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):351-7. doi: 10.1016/j.ijrobp.2007.09.043. Epub 2007 Dec 31.

PMID:
18164841
10.

Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.

Nath SK, Sandhu AP, Rose BS, Simpson DR, Nobiensky PD, Wang JZ, Millard F, Kane CJ, Parsons JK, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):435-41. doi: 10.1016/j.ijrobp.2009.08.023. Epub 2009 Nov 24.

PMID:
19939580
11.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

12.

Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.

Sveistrup J, af Rosenschöld PM, Deasy JO, Oh JH, Pommer T, Petersen PM, Engelholm SA.

Radiat Oncol. 2014 Feb 4;9:44. doi: 10.1186/1748-717X-9-44.

13.

Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.

Mendenhall NP, Li Z, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Henderson R.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):213-21. doi: 10.1016/j.ijrobp.2010.09.024. Epub 2010 Nov 17.

PMID:
21093164
14.

Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.

Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):330-7. doi: 10.1016/j.ijrobp.2007.10.004. Epub 2007 Dec 31.

PMID:
18164858
15.

Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.

Kalakota K, Liauw SL.

Urology. 2013 Jun;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. Epub 2013 Mar 26.

PMID:
23540863
16.

Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.

Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

J Urol. 2013 Aug;190(2):521-6. doi: 10.1016/j.juro.2013.02.012. Epub 2013 Feb 13.

PMID:
23415964
17.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

18.

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

PMID:
18313526
19.

A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.

Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):400-8.

PMID:
15667959
20.

Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results.

Valeriani M, Carnevale A, Osti MF, DE Sanctis V, Agolli L, Maurizi Enrici R.

Radiat Oncol. 2014 Sep 26;9:214. doi: 10.1186/1748-717X-9-214.

Supplemental Content

Support Center